{{short description|Chemical compound}} {{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 461093505 | IUPAC_name = 4-Methoxy-''N''-[2-(1-methyl-2-piperidin-1-ylethyl)phenyl]benzamide | image = Encainide.svg | image_class = skin-invert-image
<!--Clinical data--> | tradename = Enkaid | Drugs.com = {{drugs.com|CONS|encainide}} | MedlinePlus = a605040 | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | pregnancy_US = <!-- A / B / C / D / X --> | pregnancy_category = | legal_AU = <!-- Unscheduled / S2 / S4 / S8 --> | legal_UK = <!-- GSL / P / POM / CD --> | legal_US = <!-- OTC / Rx-only --> | legal_status = Withdrawn | routes_of_administration =
<!--Pharmacokinetic data--> | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion =
<!--Identifiers--> | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = 66778-36-7 | ATC_prefix = C01 | ATC_suffix = BC08 | ATC_supplemental = | PubChem = 48041 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = DB01228 | ChEMBL_Ref = {{ebicite|changed|EBI}} | ChEMBL = 315838 | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 43697 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = SY3J0147NB | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D07894 | ChEBI_Ref = {{ebicite|correct|EBI}} | ChEBI = 4788
<!--Chemical data--> | C=22 | H=28 | N=2 | O=2 | smiles = COc1ccc(C(=O)Nc2ccccc2CCC2CCCCN2C)cc1 | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C22H28N2O2/c1-24-16-6-5-8-19(24)13-10-17-7-3-4-9-21(17)23-22(25)18-11-14-20(26-2)15-12-18/h3-4,7,9,11-12,14-15,19H,5-6,8,10,13,16H2,1-2H3,(H,23,25) | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = PJWPNDMDCLXCOM-UHFFFAOYSA-N }}
'''Encainide''' (trade name '''Enkaid''') is a class Ic antiarrhythmic agent. It is no longer used because of its frequent proarrhythmic side effects.<ref>{{cite journal | vauthors = Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL | display-authors = 6 | title = Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial | journal = The New England Journal of Medicine | volume = 324 | issue = 12 | pages = 781–8 | date = March 1991 | pmid = 1900101 | doi = 10.1056/NEJM199103213241201 | doi-access = free }}</ref>
==Synthesis== thumb|500px|center|Synthesis:<ref>{{cite journal | vauthors = Dykstra SJ, Minielli JL, Lawson JE, Ferguson HC, Dungan KW | title = Lysergic acid and quinidine analogs. 2-(o-Acylaminophenethyl)piperidines | journal = Journal of Medicinal Chemistry | volume = 16 | issue = 9 | pages = 1015–20 | date = September 1973 | pmid = 4745503 | doi = 10.1021/jm00267a012 }}</ref><
== See also == *Iferanserin * Cardiac Arrhythmia Suppression Trial
== References == {{reflist}}
{{Sodium channel blockers}} {{Antiarrhythmic agents}}
Category:Antiarrhythmic agents Category:Benzanilides Category:4-Methoxyphenyl compounds Category:Piperidines Category:Sodium channel blockers Category:Withdrawn drugs
{{cardiovascular-drug-stub}}